Melanoma
Cancer Prognoses Informed by Module-Based Approach, Study Finds
Researchers highlight patient survival and other prognostic clues that can be drawn from expression data and related module-based molecular analyses on several cancer types.
FDA Approves Thermo Fisher HLA Typing Test as CDx for Immunocore Uveal Melanoma Therapy
The marketing authorization makes Thermo Fisher’s SeCore CDx HLA Sequencing System the first and so far only commercially available HLA typing companion diagnostic.
Castle Biosciences Q3 Revenues up 58 Percent on Strong Melanoma Test Volume
The company reported volume growth across its skin cancer and skin disease diagnostics as it builds a customer base for newer menu additions.
SkylineDx Gains CE-IVD Mark for Melanoma Metastasis Risk Assay
The Netherlands-based firm is partnering with Belgian company Biocartis on European commercialization of the qPCR assay, which could reduce unnecessary surgeries.
The company reported a record number of tests in the quarter led by its skin cancer menu but with notable sales in other test categories.